May 15, 2009, 06.32 PM IST
Dr Reddys Laboratories is to announce its fourth quarter FY09 results. According to CNBC-TV18 estimates, its consolidated, US GAAP (But Q4 nos will IFRS will be IFRS and not US GAAP) .
Its net sales is seen up 24% at Rs 1640 crore versus Rs1325 crore.
Its operating profit is seen up at Rs 225 crore versus Rs 172.5 crore.
Its OPM is seen at 14% versus 13%.
Its net profit is expected to go up 32% at Rs 137 crore versus Rs 102.8 crore.
Key factors to watch for:
Write offs from Betapharm expected in the range of Rs 200- 250 crore (not included in the estimates Final PAT figure may actually be loss because of this ) related to intangible impairment in Germany
-Generic Imitrex to contribute about Rs 150 Cr to the top line and Rs 40-50 crore to the net profits
Action in Dr Reddys Laboratories
Video of the day
Dec 11 2013, 09:54
- in Business
Dec 4 2013, 11:08
- in FII View
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.